The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising an sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of a gastrointestinal sphincter disorder. Gastrointestinal sphincter disorders include, but are not limited to, an achalasia of a sphincter of the gastrointestinal tract, a spastic sphincter of the gastrointestinal tract or sphincter spasms, or a hypertensive sphincter of the gastrointestinal tract.